drugset / Trial / NCT01334151
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
RandomizedCrossoverDouble-blindTreatment
Summary
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | 0.15 iu/kg | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | 0.15 iu/kg | Subcutaneous |